IP Strategy Expands GenoBank Onchain Genomic Platform to 7,000 Accounts, $6.9M BioIP
IP Strategy highlighted GenoBank’s BioIP platform on Story now supports over 7,000 genomic accounts, 150 research partnerships and $6.9 million in tokenized genomic data. GenoBank’s six smart contracts enable AI agents to micropayment-license specific gene sequences with revocable, time-limited access via Story’s IP Vault.
1. GenoBank BioIP Platform Growth
GenoBank’s BioIP platform now has over 7,000 genomic accounts, 150 research partnerships and $6.9 million in tokenized BioIP value on Story.
2. Smart Contract Infrastructure
The BioRouter system spans six smart contracts enabling AI agents to discover, pay for and license genomic data through micropayments, with each access generating a time-limited download link and revocable consent.
3. Story Protocol Integration
Integration with Story’s IP Vault allows targeted licensing of specific gene sequences such as BRCA mutations without full genome exposure, with all transactions tracked on-chain.
4. Implications for IP Strategy
IP Strategy’s on-chain token reserves support the programmable IP framework, positioning the company to benefit from growing demand for individual-owned, revenue-generating genomic assets in the expanding genomics market.